Innate Pharma (PA:IPH) — Market Cap & Net Worth
Market Cap & Net Worth: Innate Pharma (IPH)
Innate Pharma (PA:IPH) has a market capitalization of $115.22 Million (€98.56 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #18762 globally and #270 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innate Pharma's stock price €1.58 by its total outstanding shares 93829188 (93.83 Million). Also see IPH current and non-current assets for a full breakdown of the balance sheet.
Innate Pharma Market Cap History: 2015 to 2026
Innate Pharma's market capitalization history from 2015 to 2026. Data shows change from $1.49 Billion to $173.32 Million (-17.99% CAGR). Also see Innate Pharma cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Innate Pharma is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$226.34 Billion | 0.05% | #81 of 119 |
|
CAC Small90
CACS
|
$36.74 Billion | 0.31% | #32 of 64 |
|
CAC All-Tradable
CACT
|
$2.81 Trillion | 0.00% | #141 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.81 Trillion | 0.00% | #141 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.81 Trillion | 0.00% | #141 of 179 |
|
CAC PME
CAPME
|
$41.14 Billion | 0.28% | #17 of 34 |
|
CAC Health Care
FRHC
|
$239.52 Billion | 0.05% | #21 of 36 |
Weight: Innate Pharma's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Innate Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innate Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Innate Pharma stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
63.05x
Innate Pharma's market cap is 63.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.60 Billion | $56.16 Million | $12.64 Million | 28.54x | 126.79x |
| 2017 | $521.06 Million | $32.63 Million | -$48.38 Million | 15.97x | N/A |
| 2018 | $815.59 Million | $79.89 Million | $3.05 Million | 10.21x | 267.49x |
| 2019 | $653.79 Million | $68.97 Million | -$20.76 Million | 9.48x | N/A |
| 2020 | $379.77 Million | $69.77 Million | -$63.98 Million | 5.44x | N/A |
| 2021 | $487.93 Million | $12.11 Million | -$52.81 Million | 40.28x | N/A |
| 2022 | $360.90 Million | $49.64 Million | -$58.10 Million | 7.27x | N/A |
| 2023 | $287.40 Million | $51.90 Million | -$7.57 Million | 5.54x | N/A |
| 2024 | $211.93 Million | $12.62 Million | -$49.47 Million | 16.79x | N/A |
| 2025 | $175.73 Million | $2.79 Million | -$49.18 Million | 63.05x | N/A |
Competitor Companies of IPH by Market Capitalization
Companies near Innate Pharma in the global market cap rankings as of September 20, 2026. Review Innate Pharma (IPH) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Innate Pharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Innate Pharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Innate Pharma's market cap moved from $1.49 Billion to $ 173.32 Million, with a yearly change of -17.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €173.32 Million | -1.37% |
| 2025 | €175.73 Million | -17.08% |
| 2024 | €211.93 Million | -26.26% |
| 2023 | €287.40 Million | -20.36% |
| 2022 | €360.90 Million | -26.03% |
| 2021 | €487.93 Million | +28.48% |
| 2020 | €379.77 Million | -41.91% |
| 2019 | €653.79 Million | -19.84% |
| 2018 | €815.59 Million | +56.53% |
| 2017 | €521.06 Million | -67.49% |
| 2016 | €1.60 Billion | +7.90% |
| 2015 | €1.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Innate Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $115.22 Million USD |
| MoneyControl | $115.22 Million USD |
| MarketWatch | $115.22 Million USD |
| marketcap.company | $115.22 Million USD |
| Reuters | $115.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more